Skip to content

BRAINSTORM CELL THERAPEUTICS INC.

BCLI

CIK 0001137883

← back to feed
Revenue (TTM)
—
Q1 May 2026
Net Income (TTM)
−$10M
+11.3% YoY Q1 May 2026
EPS Diluted (TTM)
−$1.17
+51.9% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
—
Q1 May 2026
Net Margin
—
Q1 May 2026
Free Cash Flow (TTM)
−$7.6M
Q1 May 2026
Cash
$15K
Q1 May 2026
Total Debt
$1.33M
Q1 May 2026
Shares Outstanding
11.03M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings